News
BioSenic progresses cGvHD system and submits patent to EPO
BioSenic – a company focusing on in autoimmune and inflammatory diseases – has announced that it has submitted a vital patent in relation to the use of its ATO platform.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
BioSenic – a company focusing on in autoimmune and inflammatory diseases – has announced that it has submitted a vital patent in relation to the use of its ATO platform.